{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelofibrosis+%28MF%29&page=3", "query": { "condition": "Myelofibrosis (MF)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 90, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelofibrosis+%28MF%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelofibrosis+%28MF%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T01:27:29.577Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05835466", "title": "Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis (PMF)", "Post Essential Thrombocythemia Myelofibrosis (ET-MF)", "Post Polycythemia Vera Related Myelofibrosis (PV-MF)" ], "interventions": [ { "name": "reparixin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-07-24", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 9, "location_summary": "Tampa, Florida • Atlanta, Georgia • Buffalo, New York + 4 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05835466" }, { "nct_id": "NCT04485260", "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "KRT-232", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 36, "start_date": "2021-01-28", "completion_date": "2024-10", "has_results": false, "last_update_posted_date": "2022-05-09", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 8, "location_summary": "Duarte, California • Baltimore, Maryland • Ann Arbor, Michigan + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04485260" }, { "nct_id": "NCT00360035", "title": "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Obatoclax mesylate (GX15-070MS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gemin X", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2006-07", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2013-08-26", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00360035" }, { "nct_id": "NCT07250646", "title": "A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Secondary AML", "Myelofibrosis" ], "interventions": [ { "name": "rebecsinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aspera Biomedicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2026-05-21", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 3, "location_summary": "Duarte, California • Sacramento, California • San Diego, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07250646" }, { "nct_id": "NCT06479135", "title": "Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Post-PV MF", "Post-ET Myelofibrosis", "Primary Myelofibrosis", "MF" ], "interventions": [ { "name": "Navtemadlin", "type": "DRUG" }, { "name": "Navtemadlin placebo", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-06-03", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06479135" }, { "nct_id": "NCT02587598", "title": "Study of INCB053914 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB053914", "type": "DRUG" }, { "name": "I-DAC (Intermediate dose cytarabine)", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2015-12-29", "completion_date": "2020-08-11", "has_results": true, "last_update_posted_date": "2021-12-08", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 19, "location_summary": "Tucson, Arizona • Sacramento, California • Santa Monica, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02587598" }, { "nct_id": "NCT04576156", "title": "A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Imetelstat", "type": "DRUG" }, { "name": "Best Available Therapy (BAT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Geron Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 327, "start_date": "2021-04-12", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 12, "location_summary": "La Jolla, California • Los Angeles, California • New Haven, Connecticut + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Plantation", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04576156" }, { "nct_id": "NCT06414681", "title": "Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Myelofibrosis，MF" ], "interventions": [ { "name": "Tagraxofusp", "type": "DRUG" }, { "name": "Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-08-25", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 1, "location_summary": "Fairway, Kansas", "locations": [ { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06414681" }, { "nct_id": "NCT03441113", "title": "Extended Access of Momelotinib in Adults With Myelofibrosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Post-polycythemia Vera Myelofibrosis (Post-PV MF)", "Primary Myelofibrosis (PMF)", "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)", "Primary Myelofibrosis" ], "interventions": [ { "name": "MMB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 237, "start_date": "2018-05-03", "completion_date": "2026-12-11", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Orange, California • Stanford, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03441113" }, { "nct_id": "NCT02712905", "title": "An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors and Hematologic Malignancy" ], "interventions": [ { "name": "INCB059872", "type": "DRUG" }, { "name": "all-trans retinoic acid (ATRA)", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2016-05-05", "completion_date": "2022-04-14", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-10-03T01:27:29.577Z", "location_count": 11, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02712905" } ] }